We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
CNBC Markets · Thu, 29 Oct 2026 17:44:21 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.”
Rule-based headline sentiment: Neutral
More Stocks headlines
Linde delivers a good quarter and puts in a fix for an overhang on the stock— CNBC MarketsPolymarket reports outage on international exchange, halts trading— CNBC MarketsRare Stanley Druckenmiller post sends crypto-linked stock surging— CNBC MarketsWhy Alphabet’s stock is on track for its worst day ever after the latest results— MarketWatch
New to the fundamentals behind stories like this?
OmniFin Academy covers money basics, risk management, and reading markets — free, self-paced, no sign-up required.
Start OmniFin Academy →